For Oberoi Realty, timely launches and leaner inventory key catalysts in FY26
Oberoi Realty Ltd's March quarter (Q4FY25) was dull. Pre-sales or bookings at
₹
853 crore fell over 50% sequentially as well as year-on-year, according to provisional data.
The reading is below some analysts' estimates. For instance, Antique Stock Broking was pencilling in Q4 pre-sales of
₹
1,000 crore.
The lack of new project launches played spoilsport for the Mumbai-focused real estate developer. Thus, it could sell 78 units in Q4 versus 554 units in Q3FY25 and 227 in Q4FY24. Recall that the launch of The Jardin project at Pokhran Road in Thane and the launch of a new tower in the Elysian project at Goregaon had buoyed Q3FY25 and Q4FY24 pre-sales, respectively.
To be sure, FY25 ended on a decent note for Oberoi with pre-sales growth of about 32% year-on-year to
₹
5,266 crore. This came from selling 1.3 million square feet across 928 units. In FY24, it had sold 705 units. Oberoi added many new projects during the year, including redevelopment projects across various micro-markets in the Mumbai Metropolitan Region. This gave FY25 pre-sales a boost.
Also Read |
Oberoi Realty: Why investors have little room for optimism
Oberoi steps into FY26 with the much-anticipated foray in the Gurugram market which is crucial for maintaining pre-sales momentum and diversifying its geographical mix. Projects at Adarsh Nagar, Worli, and Tardeo in Mumbai are expected to be launched in FY26. Apart from timely new project launches, inventory liquidation at existing projects is another crucial factor to determine outlook on pre-sales and realisations.
'Average realisations surged 58% year-on-year/114% sequentially to
₹
62,117/sq ft in Q4FY25, indicating larger contribution from the Worli project, whereas the average ticket size was up 41% year-on-year/216% sequentially to
₹
10.9 crore," said a Nuvama Research report dated 21 April.
Oberoi managed to book only two units in the high-ticket marquee project Three Sixty West, located at Worli in Mumbai, in Q3FY25, much lower than the run rate of six units in the previous two quarters.
Also Read:
Realty's FY25 pre-sales goal hinges on H2 delivery
Meanwhile, a comforting factor is that Oberoi's balance sheet is in good stead aided by fundraise and robust cash collections. These have helped ease the debt burden and provide Oberoi's ability to pursue new business development opportunities.
Oberoi's shares have gained 19% in the past year, versus negative returns of the sectoral Nifty Realty index. But Nuvama cautions that the weakness in housing volumes has led to concerns about future sales growth, compelling the brokerage house to slash net asset value (a valuation metric for realty stocks) premium for the Oberoi stock to 35% from 60% earlier.
Also Read:
Realtors eye new addresses in tier-2 cities
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
5 hours ago
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
Time of India
6 hours ago
- Time of India
KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin America. Both parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June end. As with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) valuation. ART Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and India. Live Events With clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Capital. ART Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and Faridabad. Led by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine years. According to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million. "For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well." IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals. A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to queries. Moelis is the advisor in the transaction. India is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in Europe. Infertility affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and pollution. According to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%. India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall Clinic. Nova IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and TPG. Similarly, homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
Time of India
9 hours ago
- Time of India
Major 26 listed realty firms sell ₹1.62 lakh crore properties in FY25
NEW DELHI: India's 26 major listed real estate firms sold properties valuing Rs 1.62 lakh crore last fiscal, with Godrej Properties becoming largest player clocking pre-sales of nearly Rs 30,000 crore. DLF Ltd, the biggest real estate firm in terms of market capitalisation, is at the second position with record sale bookings of over Rs 21,000 crore during 2024-25, followed by Macrotech Developers (Lodha Group), Prestige Estates Projects and Signature Global . According to the data compiled from investors presentations and regulatory filings, the 26 major listed real estate companies reported a combined sales bookings or pre-sales of Rs 1,61,722 crore in the last fiscal year, a more than 20 per cent increase from 2023-24. Bulk of pre-sales (sales bookings) came from residential segment especially luxury homes, with small contribution from commercial properties. In terms of annual sales bookings, Godrej Properties emerged as the largest listed player during last fiscal with pre-sales of Rs 29,444 crore. Its pre-sales stood at Rs 22,527 crore during 2023-24. DLF's sales bookings rose to Rs 21,223 crore from Rs 14,778 crore driven by strong sales in its ultra luxury housing project The Dahlias in Gurugram. Mumbai-based Macrotech Developers Ltd reported sale bookings of Rs 17,630 crore in FY25 as against Rs 14,520 crore in the preceding year. Bengaluru-based Prestige Estates Projects clocked sale bookings of Rs 17,023 crore last fiscal as against Rs 21,040 crore in 2023-24. Delhi-NCR based Signature Global achieved sales bookings of Rs 10,290 crore as against Rs 7,270 crore. There were many real estate firms which clocked annual sales between Rs 5,000 crore and Rs 10,000 crore. Mumbai-based Aditya Birla Real Estate sold properties worth Rs 8,087 crore last fiscal, a sharp jump from Rs 3,985 crore in the preceding year. Bengaluru-based Brigade Enterprises reported a sales bookings of Rs 7,847 crore as against Rs 6,013 crore. Sobha Ltd's pre-sales fell to Rs 6,277 crore from Rs 6,644 crore. Delhi-NCR-based Max Estates sold properties worth Rs 5,321 crore last fiscal as against Rs 1,844 crore in the preceding year. Mumbai-based Oberoi Realty sold properties worth Rs 5,281 crore in FY25. Puravankara Ltd sales bookings declined to Rs 5,006 crore from Rs 5,914 crore. In below Rs 5,000 crore annual pre-sales category, Delhi-based TARC Ltd sold properties worth Rs 3,722 crore as against Rs 1,612 crore in FY24. Mumbai-based Keystone Realtors (Rustomjee) sale bookings grew to Rs 3,028 crore from Rs 2,266 crore. Mahindra Lifespace Developers' pre-sales rose to Rs 2,804 crore from Rs 2,328 crore. Pune based Kolte-Patil Developers Ltd sales fell marginally to Rs 2,791 crore from Rs 2,822 crore. Sales bookings of Sunteck Realty went up to Rs 2,531 crore from Rs 1,915 crore. Raymond Ltd sold properties worth Rs 2,310 crore last fiscal as against Rs 2,249 crore in the preceding year. Bengaluru-based Shriram Properties sales bookings fell to Rs 2,288 crore from Rs 2,362 crore. Embassy Developments clocked sales of Rs 2,031 crore last fiscal as against Rs 1,838 crore in 2023-24. There were many players that reported annual pre-sales below Rs 2,000 crore. Delhi-based Ashiana Housing Ltd reported sales bookings of Rs 1,936.75 crore during the last fiscal as against Rs 1,798.22 crore in the preceding year. Ahmedabad-based Arvind Smartspaces sold properties worth Rs 1,271 crore FY25 as against Rs 1,107 crore in the preceding year. Ajmera Realty & Infrastructure Ltd sales bookings grew to Rs 1,080 crore from Rs 1,017 crore. Arihant SuperstructuresLtd sales bookings stood at Rs 888.7 crore as against Rs 970.6 crore. Arkade Developers' sales bookings grew to Rs 773 crore from Rs 645 crore. Suraj Estate Developers sold properties worth Rs 501 crore in FY25 as against Rs 483 crore in the preceding year. Lucknow-based Eldeco Housing & Industries Ltd clocked pre-sales of Rs 337.5 crore last fiscal as against Rs 388.7 crore in the 2023-24 financial year. Sale bookings data of many listed players was not available on the stock exchanges. Market experts attributed the strong performance of listed players to a gradual shift in consumers preference towards branded and reputed players which have better track record of executing real estate projects. With lakhs of homebuyers still stuck in stalled housing projects, the prospective customers do not want to take risk on their investments.
